Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain wave study seeks early clues to psychosis

NCT ID NCT06911931

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the brain processes visual information in people with schizophrenia, bipolar disorder, or schizoaffective disorder. Researchers will use a non-invasive EEG cap to measure brain waves while participants view simple visual patterns. The goal is to find early markers of psychosis that could improve diagnosis and understanding of these conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify early brain markers for psychosis, leading to better diagnosis or monitoring tools.
What could go wrong
This is an early observational study, not a treatment trial. It may not find clear markers or lead directly to clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All Subjects * Aged 18-65 * 20/32 visual acuity or better (using in-house optical correction, if necessary) * An ability to speak English well enough to complete study assessments and to consent to the study * Subjects with Schizophrenia-Spectrum Disorder * Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5). * Subjects with Bipolar Disorder * Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5). Exclusion Criteria: * All subjects * Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following: * Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent. * Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter); * Actively intoxicated, as shown via patient self-report or staff report; * Substance use disorder in the past 3 months; * Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening); * Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation. * Being in a current manic state * Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter). * Subject has had electroconvulsive therapy (ECT) in the past 8 weeks; * Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records) * Lazy eye or squint or other known ocular pathology * Healthy Control Subjects * Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure); * Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * Case-match Control Non-ill Subjects * Any lifetime psychotic disorder (as assessed by SCID/or SSD); * Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD) * Persistent threshold psychotic symptoms * History of psychiatric hospitalization; * Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days * First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * Bipolar Subjects * Persistent threshold psychotic symptoms

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Rochester

    RECRUITING

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.